Related Experiment Video
Updated: Dec 16, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome
Wilbert Bor1, Diana A Gorog2,3
1St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
Insights
Managing patients with both acute coronary syndrome and atrial fibrillation requires balancing antithrombotic efficacy and bleeding risk. This review guides optimal treatment strategies for these complex cases.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Acute coronary syndrome (ACS) and atrial fibrillation (AF) frequently coexist in patients.
- Combination therapy (dual antiplatelet therapy and oral anticoagulation) increases bleeding risk.
Purpose of the Study:
- To review evidence for optimal antithrombotic treatment in patients with ACS and AF.
- To guide clinicians in balancing antithrombotic efficacy and bleeding risk.
Main Methods:
- Review of available clinical evidence.
- Analysis of treatment choices including anticoagulation, P2Y12 inhibitors, and genetic testing.
Main Results:
- Optimal antithrombotic strategy requires careful consideration of individual patient factors.
- Treatment decisions involve intraprocedural anticoagulation, oral anticoagulant choice/dosing, and therapy duration.
Conclusions:
- Balancing antithrombotic benefits against bleeding risks is crucial for patients with coexisting ACS and AF.
- Personalized treatment selection, potentially including genetic testing, can optimize outcomes.
Abstract:
Acute coronary syndrome and atrial fibrillation are both common and can occur in the same patient. Combination therapy with dual antiplatelet therapy and oral anticoagulation increases risk of bleeding. Where the two conditions coexist, careful consideration is needed to determine the optimal antithrombotic treatment to reduce the risks of future ischaemic events associated with both conditions. Choices can be made in intraprocedural anticoagulation, type and dosing of oral anticoagulant, duration of combination therapy, and selection of P2Y12 inhibitor including genetic testing. This review article provides an overview of the available evidence to support clinicians in finding the delicate balance between antithrombotic efficacy and bleeding risk in patients with acute coronary syndrome and atrial fibrillation.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins

